Therapeutic efficacy evaluation of the reference drug ursodeoxycholic acid and its analogues in the biliary sludge dissolution: a meta-analysis
- Authors: Kucheryavyy Y.A.1, Cheremushkin S.V.2,3
-
Affiliations:
- Ilyinskaya Hospital
- Yevdokimov Moscow State University of Medicine and Dentistry
- Central Clinical Hospital "RZD-Medicine"
- Issue: Vol 24, No 12 (2022)
- Pages: 860-864
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/144223
- DOI: https://doi.org/10.26442/20751753.2022.12.201429
- ID: 144223
Cite item
Full Text
Abstract
Aim. To compare the therapeutic efficacy of the reference drug ursodoxycholic acid (UDCA) for Russian Federation (Ursofalk) and generic UDCA preparations of other manufacturers in the solution of biliary sludge (BS).
Materials and methods. The search for studies was carried out in the electronic databases MEDLINE/PubMed, EMBASE, Cochrane, Russian Science Citation Index (RSCI) until February 2022. Inclusion criteria for the meta-analysis were controlled trials, trials using the reference drug for RF – Ursofalk in one of the groups, diagnosis and subsequent assessment of the dynamics of resolution of BS according to transabdominal ultrasound, the absence of simultaneous use of other therapy that could affect therapeutic outcomes, a documented endpoint, which reflects the percentage of the total resolution of the BS in each of the compared groups.
Results. The final analysis included 6 studies involving 671 patients with BS (324 with Ursophalc, 347 with other UDCA). When using any UDCA preparations, the generalized frequency of BS dissolution within 3 months was 52.010% (95% confidence interval – CI 36.554–67.272; I2=94.07%), and after 6 months – 78.204% (95% CI 67.840–87.024; I2=86.90%). When using the RF reference drug Ursofalk, the generalized frequency of dissolution of BS during 3 months of therapy was 64.826% (95% CI 49.242–78.941; I2=87.53%), while when using other UDCA drugs it was 39.187% (95% CI 17.520–63.390; I2=95.24%). Ursofalk was more effective than other UDCA preparations (odds ratio – OR 3.183; 95% CI 1.495-6.777; I2=74.52%). A similar trend persisted when evaluating the effectiveness of a 6-month course of therapy (OR 4.614; 95% CI 2.881–7.388; I2=26.41%). Thus, the generalized frequency of dissolution of BS in the Ursofalk groups was 88.381% (95% CI 80.890–94.198; I2=64.98%), and for other UDCA drugs – 65.978% (95% CI 60.125–71.491; I2=43.22%).
Conclusion. This meta-analysis demonstrated that the reference drug UDCA for RF (Ursofalk) is more effective than generic UDCA drugs from other manufacturers in diluting BS.
Full Text
##article.viewOnOriginalSite##About the authors
Yury A. Kucheryavyy
Ilyinskaya Hospital
Author for correspondence.
Email: proped@mail.ru
ORCID iD: 0000-0001-7760-2091
Cand. Sci. (Med.), Assoc. Prof., Ilyinskaya Hospital
Russian Federation, Glukhovo, Moscow RegionSergei V. Cheremushkin
Yevdokimov Moscow State University of Medicine and Dentistry; Central Clinical Hospital "RZD-Medicine"
Email: proped@mail.ru
ORCID iD: 0000-0002-0982-2006
Cand. Sci. (Med.), Yevdokimov Moscow State University of Medicine and Dentistry, Central Clinical Hospital "RZD-Medicine"
Russian Federation, Moscow; MoscowReferences
- Peery AF, Crockett SD, Barritt AS, et al. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. Gastroenterology. 2015;149(7):1731-41.e3. doi: 10.1053/j.gastro.2015.08.045
- Stokes CS, Lammert F. Excess Body Weight and Gallstone Disease. Visc Med. 2021;37(4):254-60. doi: 10.1159/000516418
- European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146-81. doi: 10.1016/j.jhep.2016.03.005
- Song ST, Shi J, Wang XH, et al. Prevalence and risk factors for gallstone disease: A population-based cross-sectional study. J Dig Dis. 2020;21(4):237-45. doi: 10.1111/1751-2980.12857
- Gutt C, Schläfer S, Lammert F. The Treatment of Gallstone Disease. Dtsch Arztebl Int. 2020;117(9):148-58. doi: 10.3238/arztebl.2020.0148
- Shabanzadeh DM. Incidence of gallstone disease and complications. Curr Opin Gastroenterol. 2018;34(2):81-9. doi: 10.1097/MOG.0000000000000418
- Маев И.В., Гуленченко Ю.С., Дичева Д.Т., и др. Клиническое значение билиарного сладжа как предкаменной стадии желчнокаменной болезни. Consilium Medicum. 2013;15(8):4 [Maev IV, Gulenchenko YuS, Dicheva DT, et al. The clinical significance of biliary sludge as a pre-stone stage of gallstone disease. Consilium Medicum. 2013;15(8):4 (in Russian)].
- Вихрова Т.В. Билиарный сладж и его клиническое значение. Автореф. дис. … канд. мед. наук. М., 2003 [Vikhrova TV. Biliarnyi sladzh i ego klinicheskoe znachenie. Avtoref. dis. … kand. med. nauk. Moscow, 2003 (in Russian)].
- Григорьева И.Н. Билиарный сладж. РЖГГК. 2009;19(3):32-7 [Grigorieva IN. Biliary sludge. RJGGK. 2009;19(3):32-7 (in Russian)].
- Ильченко А.А. Билиарный сладж: причины формирования, диагностика и лечение. Consilium Medicum. 2012;2:18-21 [Ilchenko AA. Biliary sludge: causes of formation, diagnosis and treatment. Consilium Medicum. 2012;2:18-21 (in Russian)].
- Абгаджава Э.З., Тельных Ю.В. Патогенетическая терапия и исходы сладжа желчного пузыря. Экспериментальная и клиническая гастроэнтерология. 2016;128(4):67-71 [Abgadzhava EZ, Telnykh YV. Pathogenetic therapy and of the gallbladder sludge outcomes. Experimental and Clinical Gastroenterology. 2016;128(4):67-71 (in Russian)].
- Минушкин О.Н., Елизаветина Г.А., Иванова О.И., Шапошникова О.Ф. Урсодезоксихолевая кислота в лечении больных с билиарным сладжем. Эффективная фармакотерапия. Гастроэнтерология. 2012;3:10-2 [Minushkin ON, Elizavetina GA, Ivanova OI, Shaposhnikova OF. Ursodeoxycholic acid in the treatment of patients with biliary sludge. Effective pharmacotherapy. Gastroenterology. 2012;3:10-2 (in Russian)].
- Казюлин А.Н., Гончаренко А.Ю., Калягин И.Е. Применение урсодезоксихолевой кислоты в профилактике и лечении желчнокаменной болезни в практике врачей «первого контакта». РМЖ. Медицинское обозрение. 2017;2:80-7 [Kazyulin AN, Goncharenko AYu, Kalyagin IE. Application of ursodezoxycolic acid for prevention and treatment of cholelithiasis in the practice of the «first contact physicians. RMJ Medical review. 2017;2:80-7 (in Russian)].
- Взаимозаменяемые лекарственные препараты (п. 4 ч. 4 ст. 3 Федерального закона от 27.12.2019 № 475-ФЗ, п. 8 постановления Правительства от 05.09.2020 № 1360) [Interchangeable medicines (clause 4, part 4, article 3 of the Federal Law of December 27, 2019 No. 475-FZ, clause 8 of Government Decree No. 1360 of September 5, 2020) (in Russian)].
- Лоранская И.Д. Функциональные расстройства билиарного тракта. М.: Форте-принт, 2013 [Loranskaya ID. Funktsional'nye rasstroistva biliarnogo trakta. Moscow: Forte-print, 2013 (in Russian)].
- Сарвилина И.В. Сравнительный клинико-экономический анализ применения препаратов урсодезоксихолевой кислоты у пациентов с желчнокаменной болезнью 1 стадии. Лечащий врач. 2015;2:64-8 [Sarvilina IV. Comparative clinical and economic analysis of the use of ursodeoxycholic acid preparations in patients with stage 1 cholelithiasis. Lechaschi Vrach. 2015;2:64-8 (in Russian)].
- Вялов С.С. Различия в эффективности лечения желчнокаменной болезни и билиарного сладжа разными препаратами урсодезоксихолевой кислоты. Consilium Medicum. 2017;19(8-2):64-8 [Vyalov SS. Differences in the effectiveness of the treatment of cholelithiasis and biliary sludge with different preparations of ursodeoxycholic acid. Consilium Medicum. 2017;19(8-2):64-8 (in Russian)]. doi: 10.26442/2075-1753_19.8.2.64-68
- Хлынов И.Б., Акименко Р.И., Гурикова И.А., и др. Билиарный сладж: опыт терапии в реальной клинической практике. Лечащий врач. 2019;4:80-3 [Khlynov IB, Akimenko RI, Gurikova IA, et al. Biliary sludge: experience of therapy in real clinical practice. Lechaschi Vrach. 2019;4:80-3 (in Russian)].
- Буторова Л.И., Ардатская М.Д., Осадчук М.А., и др. Сравнительная эффективность препаратов урсодезоксихолевой кислоты в лечении билиарного сладжа. Терапевтический архив. 2020;92(8):60-5 [Butorova LI, Ardatskaya MD, Osadchuk MA, et al. Comparative efficacy of ursodeoxycholic acid preparations in the treatment of biliary sludge. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(8):60-5 (in Russian)]. doi: 10.26442/00403660.2020.08.000700
- Бакулин И.Г., Авалуева Е.Б., Серкова М.Ю., и др. Билиарный сладж: патогенез, этиология и лекарственная терапия. Терапевтический архив. 2021;93(2):179-86 [Bakulin IG, Avalueva EB, Serkova MYu. Biliary sludge: pathogenesis, etiology and drug therapy. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(2):179-86 (in Russian)]. doi: 10.26442/00403660.2021.02.200638
- Исанбаева А.Р., Сахаутдинова Г.М. Оценка терапевтической эффективности различных препаратов урсодезоксихолевой кислоты в лечении билиарного сладжа. Терапевтический архив. 2021;93(12):1477-81 [Isanbayeva AR, Sakhautdinova GM. Evaluation of the therapeutic efficacy of various ursodeoxycholic acid preparations in the treatment of biliary sludge. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1477-81 (in Russian)]. doi: 10.26442/00403660.2021.12.201250
- Magouliotis DE, Tasiopoulou VS, Svokos AA, et al. Ursodeoxycholic Acid in the Prevention of Gallstone Formation After Bariatric Surgery: an Updated Systematic Review and Meta-analysis. Obes Surg. 2017;27(11):3021-30.
Supplementary files
